Telmisartan and enalapril have shown comparable antihypertensive efficacy in nondiabetic hypertensive patients and similar efficacy in reducing proteinuria in patients with moderate renal failure.

This study concludes that the angiotensin-receptor blocker (ARB) telmisartan was equivalent to the ACE inhibitor ramipril in preventing cardiovascular events in high-risk patients with vascular ...

Boehringer Ingelheim Pharmaceuticals has received approval for a new indication for its angiotensin II receptor blocker Micardis (telmisartan).

The FDA has approved Widaplik (telmisartan, amlodipine and indapamide) for the treatment of hypertension, including as initial treatment, to lower blood pressure.